Thank you for your interest in Molecular Medicine. The journal has recently switched publishers to BMC, who will host all back content. If you notice any missing content, please reach out to us.
Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma
Cyclin-dependent kinases 2/4/6 (CDK2/4/6) play critical roles in cell cycle progression, and their deregulations are hallmarks of hepatocellular carcinoma (HCC).
Citation: Molecular Medicine 2021 27:15